ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

1:00PM-2:30PM: Abstract Number: 2557

The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study

Abstracts: Metabolic & Crystal Arthropathies

1:00PM-2:30PM: Abstract Number: 2571

Trajectories of Physical Function in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

Abstracts: Pediatric Rheumatology – Clinical I

1:00PM-2:30PM: Abstract Number: 2536

Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium

Abstracts: Genetics, Genomics & Proteomics

1:00PM-2:30PM: Abstract Number: 2549

VISTA Deficiency Alters the Skin Immune Cell Composition and Confers Skin Sensitivity to UV Light

Abstracts: SLE – Animal Models

1:00PM-2:30PM: Abstract Number: 2581

Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study

Abstracts: SpA Including PsA – Treatment II

1:00PM-2:30PM: Abstract Number: 2584

Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial

Abstracts: SpA Including PsA – Treatment II

3:00PM-4:30PM: Abstract Number: 2603

A Human Lupus Gut Pathobiont Accelerates Systemic Inflammation, Autoantibody Production and T Cell Dysregulation

Abstracts: SLE – Etiology & Pathogenesis

3:00PM-4:30PM: Abstract Number: 2593

A Long-term Synovial Tissue 3D Model Incorporating Fibroblasts, Macrophages, Endothelial Cells, and Other Immune Cells Such as Innate Lymphoid Cells Enables Animal Model-Independent Rheumatoid Arthritis Research

Abstracts: Cytokines & Cell Trafficking

3:00PM-4:30PM: Abstract Number: 2594

A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways

Abstracts: Cytokines & Cell Trafficking

3:00PM-4:30PM: Abstract Number: 2654

Adapting and Testing a Cognitive Rehabilitation Intervention Tailored for People with Systemic Sclerosis: Acceptability, Feasibility, & Impact on Health-related Outcomes

Abstracts: ARP Interprofessional II: Psychology & Practice

3:00PM-4:30PM: Abstract Number: 2604

Altered Expression of Ecto-5′-Nucleotidase (NT5E) in SLE Patients Based on Disease-associated Genotype

Abstracts: SLE – Etiology & Pathogenesis

3:00PM-4:30PM: Abstract Number: 2616

Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases

Abstracts: Infection-related Rheumatic Disease

3:00PM-4:30PM: Abstract Number: 2644

Baseline Fibroblast Immunophenotype Predicts Clinical Improvement Among Individuals with Early Diffuse Cutaneous Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II

3:00PM-4:30PM: Abstract Number: 2625

Brain Injury Markers Correlate with Impaired Executive Function and Disease Activity in Children with Systemic Lupus Erythematosus

Abstracts: Pediatric Rheumatology – Clinical II

3:00PM-4:30PM: Abstract Number: 2623

Cardiovascular Health Is Suboptimal in Most Patients with Juvenile-Onset Lupus and Dermatomyositis: Baseline Visit Findings from the Lupus Erythematous and Dermatomyositis Stress and Cardiovascular Health Cohort Study

Abstracts: Pediatric Rheumatology – Clinical II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].